Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering/Biogen interferon suit

Executive Summary

Biogen will receive $45 mil.-$50 mil. from Schering-Plough as part of interferon alpha royalty arbitration settlement. Royalty payments on U.S. sales for Intron A, Rebetron, Rebetol and PEG-Intron will recommence Oct. 1. Schering's payment "represents a portion of the amount that was in dispute between the parties," Biogen said. "The actual amount of the payment is subject to final calculation and review." Schering ceased royalty payments to Biogen in January 2001 following a favorable appeals court decision on the scope of Biogen's patents...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS040665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel